106 related articles for article (PubMed ID: 1642855)
21. [Observations of properties of the L-form of M. tuberculosis induced by the antituberculosis drugs].
Wang H; Chen Z
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Jan; 24(1):52-5. PubMed ID: 11802941
[TBL] [Abstract][Full Text] [Related]
22. Antituberculosis agents. IX. In vitro antimycobacterial activity of N-(2-phenyl-2-oxoethyl) and N-[2-(4-fluorophenyl)-2-oxoethyl]ciprofloxacin derivatives against some drug-resistant strains of Mycobacterium tuberculosis and Mycobacterium avium isolates.
Foroumadi A; Soltani F
Boll Chim Farm; 2003; 142(6):248-50. PubMed ID: 14606264
[TBL] [Abstract][Full Text] [Related]
23. [Resistance rates of Mycobacterium tuberculosis complex strains isolated from clinical specimens].
Aydın F; Kaklıkkaya N; Bayramoğlu G; Ozkul G; Buruk K; Dinç U; Köse T; Dede R
Mikrobiyol Bul; 2011 Jan; 45(1):36-42. PubMed ID: 21341157
[TBL] [Abstract][Full Text] [Related]
24. Multiple drug-susceptibility screening in Mycobacterium bovis: new nucleotide polymorphisms in the embB gene among ethambutol susceptible strains.
Marianelli C; Armas F; Boniotti MB; Mazzone P; Pacciarini ML; Di Marco Lo Presti V
Int J Infect Dis; 2015 Apr; 33():39-44. PubMed ID: 25554388
[TBL] [Abstract][Full Text] [Related]
25. Radiometric and conventional drug susceptibility testing of Mycobacterium tuberculosis.
Hoel T; Eng J
APMIS; 1991 Nov; 99(11):977-80. PubMed ID: 1958354
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility of south Indian strains of Mycobacterium tuberculosis to tuberactinomycin.
Selvakumar N; Kumar V; Acharyulu GS; Rehman F; Paramasivan CN; Prabhakar R
Indian J Med Res; 1992 May; 95():101-4. PubMed ID: 1506058
[TBL] [Abstract][Full Text] [Related]
27. In-vitro activity of ciprofloxacin combined with either fusidic acid or rifampicin against Staphylococcus aureus.
Røder BL; Gutschik E
J Antimicrob Chemother; 1989 Mar; 23(3):347-52. PubMed ID: 2732119
[TBL] [Abstract][Full Text] [Related]
28. In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and -resistant Staphylococcus aureus.
Drugeon HB; Caillon J; Juvin ME
J Antimicrob Chemother; 1994 Dec; 34(6):899-907. PubMed ID: 7730233
[TBL] [Abstract][Full Text] [Related]
29. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
[TBL] [Abstract][Full Text] [Related]
30. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis.
Dickinson JM; Aber VR; Mitchison DA
Am Rev Respir Dis; 1977 Oct; 116(4):627-35. PubMed ID: 411404
[TBL] [Abstract][Full Text] [Related]
31. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance.
Casal M; Ruiz P; Herreras A
Int J Tuberc Lung Dis; 2000 Jun; 4(6):588-91. PubMed ID: 10864193
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
[TBL] [Abstract][Full Text] [Related]
33. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Heifets LB; Lindholm-Levy PJ
Tubercle; 1987 Dec; 68(4):267-76. PubMed ID: 3138801
[TBL] [Abstract][Full Text] [Related]
34. Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods.
Lee CN; Heifets LB
Am Rev Respir Dis; 1987 Aug; 136(2):349-52. PubMed ID: 3619193
[TBL] [Abstract][Full Text] [Related]
35. Mutations in rpoB and fusA cause resistance to rifampicin and fusidic acid in methicillin-resistant Staphylococcus aureus strains from a tertiary hospital in Malaysia.
Lim KT; Teh CS; Yusof MY; Thong KL
Trans R Soc Trop Med Hyg; 2014 Feb; 108(2):112-8. PubMed ID: 24336696
[TBL] [Abstract][Full Text] [Related]
36. In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs.
Marinis E; Legakis NJ
J Antimicrob Chemother; 1985 Oct; 16(4):527-30. PubMed ID: 2933382
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of proportion method in Löwenstein-Jensen medium with the BACTEC 460 TB system for antimycobacterial susceptibility testing of Mycobacterium tuberculosis isolates].
Gül Yurtsever S; Biçmen C; Gündüz AT; Ozkütük N; Salman S; Demirci M
Mikrobiyol Bul; 2011 Oct; 45(4):623-31. PubMed ID: 22090293
[TBL] [Abstract][Full Text] [Related]
38. Drug susceptibility of Spanish Mycobacterium tuberculosis complex isolates from animals.
Romero B; Aranaz A; Bezos J; Alvarez J; de Juan L; Tariq Javed M; Mateos A; Gómez-Mampaso E; Domínguez L
Tuberculosis (Edinb); 2007 Nov; 87(6):565-71. PubMed ID: 17900988
[TBL] [Abstract][Full Text] [Related]
39. [In vitro activity of ofloxacin and ciprofloxacin against Mycobacterium tuberculosis strains].
Aysev AD
Mikrobiyol Bul; 1993 Jan; 27(1):31-5. PubMed ID: 8421440
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
Aragón LM; Garrigó M; Moreno C; Español M; Coll P
J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
